Open-access Coexistence of 46,XX gonadal dysgenesis and Mayer-Rokitansky-Küster-Hauser syndrome: a rare clinical case

ABSTRACT

Mayer-Rokitansky-Küster-Hauser syndrome is characterized by congenital absence or hypoplasia of the uterus and the upper two-thirds of the vagina, while gonadal dysgenesis is a primary ovarian defect in females. The coexistence of these two conditions is exceedingly rare. In this case report, we present a 15-year-old female who presented with primary amenorrhea and absent breast development. She exhibited no facial dysmorphism, and genital examination revealed normal female external genitalia. Laboratory tests were consistent with hypergonadotropic hypogonadism. Pelvic ultrasound revealed an atrophic uterus, with the ovaries not clearly visualized. Pelvic magnetic resonance imaging identified a rudimentary uterine cervix, vaginal hypoplasia with fibrotic band, and bilateral rudimentary adnexa. Karyotyping showed a normal 46,XX pattern. Exploratory laparoscopy with left oophorectomy was performed; histological examination of the ovary revealed stromal tissue with a cortex completely devoid of follicular components, consistent with a streak gonad. A diagnosis of 46,XX gonadal dysgenesis in association with Mayer-Rokitansky-Küster-Hauser syndrome was established. Pubertal induction was initiated at the age of 17, and the patient is currently maintained on hormone replacement therapy.

Keywords:
Amenorrhea; gonadal dysgenesis; sex differentiation disorders

INTRODUCTION

Primary amenorrhea is defined as the absence of menarche and requires clinical investigation when menstrual onset has not occurred by 15 years of age or within three years of the onset of breast development (1). The diagnostic approach relies on careful clinical assessment, including evaluation of secondary sexual characteristics, followed by hormonal profiling, pelvic imaging, and karyotyping (2).

Among the recognized etiologies, 46,XX gonadal dysgenesis is a disorder of ovarian development characterized by absent or underdeveloped ovaries, normal female external genitalia, and impaired gonadal function, which may result from genetic defects affecting gonadal differentiation or estrogen synthesis (1,3). Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is another important cause of primary amenorrhea, resulting from abnormal development of the Müllerian ducts and leading to agenesis or hypoplasia of the uterus and upper vagina in individuals with a normal 46,XX karyotype (4). While each condition is a recognized cause of primary amenorrhea, their concurrence is exceedingly rare and has been only rarely described in the literature.

CASE PRESENTATION

We the case of a 15-year-old female evaluated for primary amenorrhea and delayed pubertal development, with absent breast maturation. She was born to consanguineous parents with no family history of primary amenorrhea, infertility, or other relevant hereditary disorders. Her birth, perinatal, and neonatal histories were uneventful. Her medical history included overweight, metabolic-associated fatty liver disease, and attention-deficit hyperactivity disorder. On physical examination, her height was 162.5 cm and weight was 77 kg, yielding a body mass index of 29 kg/m2. Pubertal assessment revealed breast and pubic hair development consistent with Tanner stage II, and a complete absence of axillary hair. There were no signs of hirsutism, facial dysmorphism, cervical webbing, or skeletal abnormalities. Genital examination showed normal female external genitalia.

Laboratory testing revealed a hormonal profile compatible with hypergonadotropic hypogonadism (Table 1). Pelvic ultrasound revealed an atrophic uterus measuring 25 × 10 × 21 mm, and the ovaries were not visualized; no masses were detected in the adnexal regions. Pelvic magnetic resonance imaging identified a rudimentary uterine cervix (37 × 7 × 11 mm), vaginal hypoplasia with fibrotic bands, and bilateral rudimentary adnexa (Figure 1).

Table 1
Initial hormonal profile of the patient

Figure 1
Sagittal T2-weighted magnetic resonance imaging of the pelvis showing the uterine remnant small and hypoplastic.

Cytogenetic analysis showed a normal 46,XX karyotype, and fluorescence in situ hybridization with targeted probes confirmed theabsence of Y -chromosome material. A molecular study utilizing next-generation sequencing did not identify pathogenic variants in candidate genes related to sexual differentiation, including BMP15, FOXL2, FSHR, LHCGR, NOBOX, NR5A1, and WNT4. Exploratory laparoscopy with left oophorectomy was performed, and histology of the ovary showing stromal tissue with a cortex completely lacking follicular components, consistent with a streak gonad.

These findings supported diagnosis of 46,XX gonadal dysgenesis concurrent with MRKH syndrome. Pubertal induction was induced at the age 17 using transdermal estrogen, and two years later, progesterone was added. At present, the patient is treated with oral progesterone 200 mg for 12 days per cycle and 17β-estradiol 25 mcg via transdermal patch every 4 days.

Two years after the initiation of pubertal induction, the patient progressed to Tanner stage III breast development, yet spontaneous menstruation did not occur. Long-term follow-up, including bone mineral density assessment four years after treatment initiation, demonstrated age-appropriate bone density, indicating adequate skeletal protection with hormone replacement therapy. Despite these favorable outcomes, infertility remains an irreversible sequela due to the permanent absence of functional ovarian tissue and Müllerian structures.

DISCUSSION

This case exemplifies the unusual coexistence of two distinct and established causes of primary amenorrhea. Gonadal dysgenesis, the most common cause of primary amenorrhea, is typically associated with gonadal failure and absent or delayed secondary sexual development. Concurrently, this patient also met criteria MRKH syndrome, the second most frequent cause, a combination that is exceptionally uncommon in clinical practice (5).

The prevalence of 46,XX gonadal dysgenesis is estimated to be less than 1 in 10,000 live births. Affected individuals are phenotypically female without genital ambiguity. In the absence of X-chromosome abnormalities, this disorder is thought to result from mutations in genes essential for ovarian development and function, reflecting considerable genetic heterogeneity (6).

MRKH syndrome, or Müllerian aplasia, is a congenital condition marked by absent or underdeveloped uterine structures and the upper portion of the vagina in individuals with a normal 46,XX karyotype. Its prevalence is approximately 1 in 4,500 female births. MRKH arises from disrupted Müllerian duct development during the fifth to sixth weeks of embryogenesis, the critical period for normal formation of the uterus, cervix, and upper two-thirds of the vagina (7). Clinically, MRKH is distinguished as type I, involving isolated uterovaginal aplasia, and type II, which includes uterovaginal anomalies in combination with extragenital malformations (7).

Simultaneous 46,XX gonadal dysgenesis and MRKH syndrome is rare, with few cases reported. Levinson and cols. (8) reported the first documented case in a 17-year-old female with short stature, vaginal agenesis, absent secondary sexual development, and no identifiable internal genital organs or gonads.

Delayed pubertal progression, Tanner stage II breast development at age 15, complete absence of axillary hair, and primary amenorrhea all reflect long-standing estrogen deficiency. Laboratory findings of hypergonadotropic hypogonadism further supported primary ovarian failure. In contrast, isolated MRKH syndrome typically presents in adolescents with normal pubertal development and preserved ovarian function, and normal secondary sexual characteristics, who present primarily because of primary amenorrhea (4). Therefore, the markedly impaired breast development observed in this patient indicated that Müllerian agenesis alone could not account for the phenotype.

As with previous case reports, patients with this rare combination typically present with a normal female phenotype, primary amenorrhea, delayed or absent pubertal progression, and biochemical evidence of hypergonadotropic hypogonadism (5). Importantly, the absence of dysmorphic stigmata such as short stature, webbed neck, or skeletal anomalies made Turner syndrome and other chromosomal syndromes unlikely, although these conditions should still be considered in similar presentations. Likewise, the absence of hirsutism or clinical signs of androgen excess argued against hyperandrogenic conditions (1).

In this patient, who was born to consanguineous parents, the coexistence of 46,XX gonadal dysgenesis and MRKH syndrome raises the possibility that these rare disorders may share a common developmental or genetic etiology, While MRKH syndrome results from abnormal development of the Müllerian ducts and gonadal dysgenesis reflects primary ovarian failure, both conditions involve disruptions of early urogenital embryogenesis (5). Parental consanguinity supports a hypothesis of autosomal recessive disorder affecting pathways critical to both gonadal and Müllerian development (4).

Multiple genes have been implicated in 46,XX gonadal dysgenesis and premature ovarian insufficiency. Biallelic loss-of-function variants in FSHR impair ovarian responsiveness to follicle-stimulating hormone, resulting in hypergonadotropic hypogonadism with minimal or absent follicular development. Variants in BMP15 have been linked to defective folliculogenesis and oocyte maturation, while NR5A1 mutations are associated with a spectrum ranging from 46,XY disorders of sex development to 46,XX premature ovarian insufficiency. Mutations in STAG3 have emerged as an important gene in 46,XX gonadal dysgenesis, highlighting the role of meiotic dysfunction in early ovarian failure. Additional genes involved in ovarian reserve formation and maintenance, including NOBOX and FOXL2, have also been associated with premature ovarian insufficiency, though genotype–phenotype correlations are variable (9–11).

In this context, PSMC3IP/HOP2 and NUP107 are particularly relevant, having been discovered in consanguineous families affected by 46,XX gonadal dysgenesis. These individuals exhibited absent spontaneous puberty, primary amenorrhea, hypergonadotropic hypogonadism, uterine hypoplasia, and streak gonads, supporting the role of recessive defects in key ovarian developmental pathways (12,13).

In our patient, whole-exome sequencing was performed, but analysis was initially limited to a targeted set of candidate genes guided by the presenting clinical features. This may explain why relevant genes such as PSMC3IP/HOP2 and NUP107 were not prioritized at that stage. Therefore, the absence of pathogenic variants in the analyzed panel does not exclude a genetic etiology but rather highlights the limitations of phenotypic-driven targeted testing in genetically heterogeneous disorders. Given the parental consanguinity and the severe ovarian phenotype, broad reanalysis of exome data is warranted, including extended genes involved in meiosis, homologous recombination, DNA repair, oocyte development, folliculogenesis, and gonadal differentiation.

In this setting, exploratory laparoscopy was crucial in achieving a definitive diagnosis. Laparoscopy revealed a rudimentary uterine remnant fibrous Müllerian bands in the expected anatomic position, as well as vaginal hypoplasia. Both ovaries were replaced by bilateral streak gonads, which appeared as thin, pale, and fibrous structures. Subsequent histopathological examination confirmed streak gonads, thereby establishing the diagnosis of 46,XX gonadal dysgenesis and confirming its coexistence with MRKH syndrome.

Delayed recognition of gonadal failure in adolescents can have significant adverse consequences. Prolonged estrogen deficiency during adolescence may compromise bone mineral accrual, increasing future risk of osteopenia and osteoporosis. Late initiation of pubertal induction may also adversely affect psychosocial health, body image, and psychosexual development. Hormone replacement therapy is the cornerstone of management, aiming to mimic physiological pubertal progression with gradual estrogen replacement followed by introduction of progestogen when indicated. Early diagnosis is essential to allow timely pubertal induction, optimize peak bone mass, promote secondary sexual development, and ensure multidisciplinary psychological, gynecological, and reproductive support (5,14).

In the present case, progression to Tanner stage III breast development two years after hormone therapy supports an effective response and ongoing pubertal maturation. Furthermore, normal bone mineral density at four-year follow-up indicates favorable clinical outcomes (14). These findings reinforce the importance of early endocrine intervention, individualized long-term hormone therapy, and regular monitoring of bone health in complex disorders of gonadal development.

CONCLUSION

Although these conditions are common causes of primary amenorrhea, the coexistence of gonadal dysgenesis and MRKH syndrome is exceptionally rare. The diagnostic process is particularly challenging and should be based on a combination of clinical suspicion, laboratory findings, and imaging studies. In this case, with a negative molecular analysis, exploratory surgery and histological evaluation were essential for establishing the diagnosis. This case also illustrates the challenges of managing pubertal development and the importance of preserving bone health.

Funding:

this work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability:

datasets related to this article will be available upon request to the corresponding author.

REFERENCES

  • 1 Seppä S, Kuiri-Hänninen T, Holopainen E, Voutilainen R. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary amenorrhea and female delayed puberty. Eur J Endocrinol. 2021 May 4;184(6):R225-R242. doi: 10.1530/EJE-20-1487.
    » https://doi.org/10.1530/EJE-20-1487
  • 2 Yoon JY, Cheon CK. Evaluation and management of amenorrhea related to congenital sex hormonal disorders. Ann Pediatr Endocrinol Metab. 2019 Sep;24(3):149-157. doi: 10.6065/apem.2019.24.3.149.
    » https://doi.org/10.6065/apem.2019.24.3.149
  • 3 Rocha VB, Guerra-Júnior G, Marques-de-Faria AP, de Mello MP, Maciel-Guerra AT. Complete gonadal dysgenesis in clinical practice: the 46,XY karyotype accounts for more than one third of cases. Fertil Steril. 2011 Dec;96(6):1431-4. doi: 10.1016/j.fertnstert.2011.09.009.
    » https://doi.org/10.1016/j.fertnstert.2011.09.009
  • 4 Herlin MK, Petersen MB, Brännström M. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update. Orphanet J Rare Dis. 2020 Aug 20;15(1):214. doi: 10.1186/s13023-020-01491-9.
    » https://doi.org/10.1186/s13023-020-01491-9
  • 5 Ambachew R, Gulilat A, Aberra T, Terefework Z, Bedilu W, Tarekegn G, et al. A rare case of 46,XX gonadal dysgenesis, Mayer-Rokitansky-Kuster-Hauser syndrome, pituitary and thyroid hypoplasia. Endocrinol Diabetes Metab Case Rep. 2022 Jan 1;2022:21-0103. doi: 10.1530/EDM-21-0103.
    » https://doi.org/10.1530/EDM-21-0103
  • 6 Kebaili S, Chaabane K, Mnif MF, Kamoun M, Kacem FH, Guesmi N, et al. Gonadal dysgenesis and the Mayer-Rokitansky-Kuster-Hauser Syndrome in a girl with a 46, XX karyotype: A case report and review of literature. Indian J Endocrinol Metab. 2013 May;17(3):505-8. doi: 10.4103/2230-8210.111663.
    » https://doi.org/10.4103/2230-8210.111663
  • 7 Al Dandan O, Hassan A, Alsaihati A, Aljawad L, Almejhim F. A rare form of Mayer-Rokitansky-Küster-Hauser syndrome: Case report and review of literature. Case Rep Womens Health. 2019 Aug 6;24:e00137. doi: 10.1016/j.crwh.2019.e00137.
    » https://doi.org/10.1016/j.crwh.2019.e00137
  • 8 Levinson G, Zárate A, Guzmán-Toledano R, Canales ES, Jiménez M. An XX female with sexual infantilism, absent gonads, and lack of Müllerian ducts. J Med Genet. 1976 Feb;13(1):68-9. doi: 10.1136/jmg.13.1.68.
    » https://doi.org/10.1136/jmg.13.1.68
  • 9 Délot EC, Papp JC; DSD-TRN Genetics Workgroup; Sandberg DE, Vilain E. Genetics of Disorders of Sex Development: The DSD-TRN Experience. Endocrinol Metab Clin North Am. 2017 Jun;46(2):519-537. doi: 10.1016/j.ecl.2017.01.015.
    » https://doi.org/10.1016/j.ecl.2017.01.015
  • 10 Fortuño C, Labarta E. Genetics of primary ovarian insufficiency: a review. J Assist Reprod Genet. 2014 Dec;31(12):1573-85. doi: 10.1007/s10815-014-0342-9.
    » https://doi.org/10.1007/s10815-014-0342-9
  • 11 Bouilly J, Roucher-Boulez F, Gompel A, Bry-Gauillard H, Azibi K, Beldjord C, et al. New NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expression. J Clin Endocrinol Metab. 2015;100(3):994-1001. doi: 10.1210/jc.2014-2761.
    » https://doi.org/10.1210/jc.2014-2761
  • 12 Weinberg-Shukron A, Renbaum P, Kalifa R, Zeligson S, Ben-Neriah Z, Dreifuss A, et al. A mutation in the nucleoporin-107 gene causes XX gonadal dysgenesis. J Clin Invest. 2015 Nov 2;125(11):4295-304. doi: 10.1172/JCI83553.
    » https://doi.org/10.1172/JCI83553
  • 13 Zangen D, Kaufman Y, Zeligson S, Perlberg S, Fridman H, Kanaan M, et al. XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. Am J Hum Genet. 2011 Oct 7;89(4):572-9. doi: 10.1016/j.ajhg.2011.09.006.
    » https://doi.org/10.1016/j.ajhg.2011.09.006
  • 14 Yatsenko SA, Witchel SF, Gordon CM. Primary Amenorrhea and Premature Ovarian Insufficiency. Endocrinol Metab Clin North Am. 2024 Jun;53(2):293-305. doi: 10.1016/j.ecl.2024.01.009.
    » https://doi.org/10.1016/j.ecl.2024.01.009

Disclosure:

the authors declare that there are no conflicts of interest related to this work.

Correspondence to:

Margarida Antunes de Oliveira, manoliveira@ulslo.min-saude.pt

Associated editor:

Letícia F. Gontijo Silveira

Publication Dates

  • Publication in this collection
    13 Nov 2026
  • Date of issue
    2026

History

  • Received
    24 Mar 2026
  • Accepted
    22 June 2026
location_on
Sociedade Brasileira de Endocrinologia e Metabologia Rua Botucatu, 572 - Conjuntos 81/83, CEP: 04023-061 , Tel: +55 (11) 5575-0311 / +55 (11) 9 9768-6933 - São Paulo - SP - Brazil
E-mail: aem.editorial.office@endocrino.org.br
rss_feed Acompañe los números de esta revista en su lector de RSS
Ir para arriba